Skip to content Skip to sidebar Skip to footer

Tracking and Preventing the Spread of Antimicrobial Resistance Fungus in Healthcare Settings

Health officials have turned their attention to the rapid propagation of a fungus that has been identified as an imperative antimicrobial resistance threat within healthcare facilities. This fungus, known as Candida auris or C. auris, possesses characteristics that make it a significant concern, from its resilience against multiple antifungal drugs to its capacity to cause…

Read more

Addressing the CDC’s Ineffectual Approach in Curtailing the Spread of Candida auris: A Time for Reform

The incidence of Candida auris, a deadly fungal infection, is escalating alarmingly in numerous hospitals across the United States, causing an increasing number of infections and fatalities. According to data from the American Journal of Infection Control, this invasive fungal infection has been identified in half the states, including New York, with an exponential increase…

Read more

Confronting the Candida Auris Fungus Menace: A Call for Transparency, Technology, and Targeted Approach from the CDC

The United States continues to grapple with a lethal enemy propagating within hospital walls: Candida auris, a drug-resistant fungus that has been thriving unchecked. The story of this dangerous pathogen adds a chilling chapter to the nation's healthcare narrative, with its presence now recorded in 29 states. The threat level of this fungus is reflected…

Read more

Understanding and Controlling the Rapid Spread of the Drug-Resistant Fungus, Candida Auris

Healthcare facilities across the United States are encountering an escalating challenge— the rapidly proliferating drug-resistant fungus, Candida auris. This yeast infection is causing widespread concern among health officials due to its growing prevalence, high mortality rate, and resistance to several antifungal medications. Since its initial detection on U.S. soil back in 2016, reports of Candida…

Read more

Recent Advances in Infection Prevention: Antiviral Prophylaxis, Control of Multidrug-Resistant Microbes & Increase in Candida auris Cultures

The most recent revelations from an international phase 3 clinical trial showcase that those who commenced the antiviral drug ensitrelvir within 72 hours after a family member tested positive for COVID-19 had substantially decreased likelihood of infection. Shionogi, a Japanese pharmaceutical conglomerate, created ensitrelvir, which is currently permitted in Japan for handling mild to moderate…

Read more

Navigating the Complexities of Controlling Candida Auris in High-Risk Healthcare Settings: Lessons from a Burn ICU Outbreak

An outbreak of multidrug-resistant Candida auris in a Burn Intensive Care Unit (BICU) in Illinois has brought the continuing challenges of infection regulation to light in high-aspect clinical environments. Despite intensive containment endeavours, Candida auris, a novel fungal pathogen with extensive drug resistance and environmental persistence, continued to propagate, illustrating a dire need for advanced…

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[yikes-mailchimp form="1"]